Funded Biotechnology Startups in San Diego
San Diego's biotechnology sector logged 50 funding rounds between March 2024 and November 2025, with disclosed amounts spanning from $500K (Modulo Bio, Feb…
San Diego's biotechnology sector logged 50 funding rounds between March 2024 and November 2025, with disclosed amounts spanning from $500K (Modulo Bio, February 2025) to $500M (Crinetics Pharmaceuticals, October 2024). The three largest raises — Crinetics at $500M, Avidity Biosciences at $345M (August 2024), and Element Biosciences at a $277M Series D (July 2024) — anchor the upper range, while 29 of the 45 disclosed-amount rounds closed below $50M. Therapeutic breadth is visible across the dataset: neuroscience draws capital through Aspen Neuroscience's $115M Series C (November 2025) and Timberlyne Therapeutics' $180M Series A (January 2025); RNA biology appears via Avidity Biosciences; genomics instrumentation through Element Biosciences. Twenty-eight of the 50 records carry a "Series Unknown" or "Venture – Series Unknown" label, reflecting companies that reported capital raised without a formal stage classification.
Most recent rounds
50 shownRelated listings
Frequently asked
What are the largest disclosed rounds in this dataset?
Nine rounds reached $100M or more. The top five are Crinetics Pharmaceuticals at $500M (October 2024), Avidity Biosciences at $345M (August 2024), Element Biosciences at $277M Series D (July 2024), Timberlyne Therapeutics at $180M Series A (January 2025), and Engrail Therapeutics at $157M (March 2024). Alterome Therapeutics ($132M Series B), Aspen Neuroscience ($115M Series C), Zura Bio ($113M), and AnaptysBio ($100M) round out the nine.
How do funding stages break down across these 50 companies?
"Series Unknown" is the most common classification, covering 25 of the 50 records, and "Venture – Series Unknown" accounts for three more — together representing 28 entries where amounts were disclosed but stage was not labeled. Among formally staged rounds: six are Series A, five Series B, five Seed, three Series C, one Series D (Element Biosciences, $277M), and two records carry no stage designation at all.
Which companies closed the most recent rounds?
The three freshest entries closed November 18–19, 2025: Aspen Neuroscience (Series C, $115M), Eclipse Bioinnovations ($5M), and VST Bio ($29M). Tr1x raised $50M in October 2025 and VedaBio closed a $25M Series A in September 2025.
What does the seed-stage pipeline look like here?
Five companies raised labeled Seed rounds: Aizen Therapeutic ($13M, November 2024), Synvect ($3M, March 2025), Trio Pharmaceuticals ($3M, December 2024), Mithradote Bio ($1M, October 2024), and Inocras (undisclosed, December 2024). Several Series A companies with undisclosed amounts — Zafrens (February 2025) and Alida Biosciences ($8M, June 2024) — add further early-stage entries.
Which companies in this dataset have reached Series C or later?
Four companies are at Series C or beyond. Element Biosciences is the only Series D entrant, raising $277M in July 2024. The three Series C companies are Aspen Neuroscience ($115M, November 2025), Aardvark Therapeutics ($85M, May 2024), and Cortechs.ai (undisclosed amount, November 2024).
How many rounds have undisclosed amounts, and which companies are they?
Five of the 50 records list amounts as undisclosed: Pimera Therapeutics (Series Unknown, June 2025), Zafrens (Series A, February 2025), Resolute Science (Series Unknown, February 2025), Inocras (Seed, December 2024), and Cortechs.ai (Series C, November 2024). The remaining 45 entries include a specific dollar figure.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.